Clinical trial
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage…
NCT00363285 · St. Bartholomew's Hospital, Other · Unknown status
Key facts
| NCT number | NCT00363285 |
|---|---|
| Title | Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer |
| Official title | Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer |
| Lead sponsor | St. Bartholomew's Hospital, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | gonadotrophin releasing hormone, cyproterone acetate, quality-of-life assessment |
| Enrollment | 900 |
| Start date | Jan 1, 2003 |
| First posted | Aug 15, 2006 |
| Last update posted | Aug 26, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: